A study of Tendoncel (Platelet lysate based cell therapy) for the treatment of chronic grade 3 lateral epicondylitis, (severe) tendon injury.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Platelet-lysate-based-cell-therapy-Celixir (Primary)
- Indications Tennis elbow
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2017 New trial record
- 30 Jun 2015 Accordign to the Celixir media release, the endpoints, Improvement in tendon injury, assessed with DASH (Disabilities of the Arm, Shoulder and Hand) PRTEE (Patient-Rated Tennis Elbow Evaluation) has been met.